Inhibikase Therapeutics
IKT
IKT
47 hedge funds and large institutions have $113M invested in Inhibikase Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
5.3% less ownership
Funds ownership: 74.53% → 69.23% (-5.3%)
31% less capital invested
Capital invested by funds: $163M → $113M (-$50M)
Holders
47
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$1.69M | |
| 2 | +$1.11M | |
| 3 | +$340K | |
| 4 |
Goldman Sachs
New York
|
+$267K |
| 5 |
Jane Street
New York
|
+$255K |
Top Sellers
| 1 | -$1.27M | |
| 2 | -$476K | |
| 3 | -$112K | |
| 4 |
AGM
Alpine Global Management
New York
|
-$96.5K |
| 5 |
Squarepoint
New York
|
-$92.3K |
